Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E47.40 EPS (ttm)1.46 Insider Own0.10% Shs Outstand2.72B Perf Week4.53%
Market Cap187.54B Forward P/E15.05 EPS next Y4.59 Insider Trans-13.68% Shs Float2.67B Perf Month10.48%
Income3.94B PEG6.53 EPS next Q1.12 Inst Own75.60% Short Float0.69% Perf Quarter16.77%
Sales41.26B P/S4.55 EPS this Y29.20% Inst Trans-0.40% Short Ratio1.96 Perf Half Y22.69%
Book/sh12.12 P/B5.70 EPS next Y7.27% ROA1.50% Target Price70.52 Perf Year11.68%
Cash/sh2.80 P/C24.70 EPS next 5Y7.26% ROE3.90% 52W Range52.83 - 69.00 Perf YTD22.73%
Dividend1.92 P/FCF11720.99 EPS past 5Y-1.90% ROI8.70% 52W High0.09% Beta0.82
Dividend %2.78% Quick Ratio1.00 Sales past 5Y-3.20% Gross Margin68.00% 52W Low30.72% ATR0.90
Employees69000 Current Ratio1.30 Sales Q/Q5.40% Oper. Margin12.30% RSI (14)76.70 Volatility1.43% 1.44%
OptionableYes Debt/Eq0.72 EPS Q/Q-10.50% Profit Margin3.30% Rel Volume0.84 Prev Close68.85
ShortableYes LT Debt/Eq0.61 EarningsJul 27 BMO Payout377.30% Avg Volume9.37M Price69.06
Recom2.10 SMA205.52% SMA509.26% SMA20018.16% Volume7,843,205 Change0.31%
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Aug-17-18 05:43PM  (OFFICIAL)-UPDATE 2-Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16) Reuters
10:18AM  Merck, Eisai Get FDA Approval for Lenvima Label Expansion Zacks
09:49AM  4 Mega-Cap Stocks to Buy As Theyre Thrust Into the Spotlight InvestorPlace
09:34AM  Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication Zacks
08:03AM  FDA approves Bristol-Myers' Opdivo for small cell lung cancer Reuters
08:00AM  Healthy Interactions and Merck Announce Launch of Digital Health Platform Designed to Enhance Patient Engagement in Diabetes Management PR Newswire
08:00AM  Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC) PR Newswire
05:25AM  WHO expects more Ebola cases in Congo, can't reach no-go areas Reuters
Aug-16-18 06:33PM  Japan's Eisai sets price tag of about $16,000 on liver cancer drug Reuters
04:11PM  Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC) PR Newswire
10:08AM  Pain Therapeutics' Shares Rally on Alzheimer's Study Grant Zacks
01:14AM  Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance Reuters
Aug-15-18 03:05PM  FANG Stocks Take Heat As Distribution Hits Nasdaq; Netflix Slumps 3.5% Investor's Business Daily
09:56AM  Agenus (AGEN) Delivering Well on Its Pipeline Candidates Zacks
Aug-14-18 06:39PM  Congo deploys experimental Ebola treatment as cases rise Reuters
10:13AM  Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release Zacks
Aug-13-18 07:38AM  The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers Zacks
Aug-10-18 11:16AM  Top Research Reports with Q2 Earnings Analysis: Merck, CVS Health, CME Group & More Zacks
10:48AM  You Better Be Careful with Merck Stock, Especially at These Highs InvestorPlace
10:33AM  In $270M Peninsula vaccine company buyout, small players look to be big shots American City Business Journals
09:32AM  Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat Zacks
08:52AM  Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus Zacks
Aug-09-18 04:33PM  The Brief, August 9 Barrons.com
01:16PM  [$$] Merck KGaA Renews Commitment to U.S. Presence The Wall Street Journal
06:52AM  Deleveraging Still Remains a Top Priority, Says Merck KGaA's CFO Bloomberg Video
06:52AM  Deleveraging Still Remains a Top Priority, Says Merck KGaA's CFO Bloomberg
04:46AM  [$$] European Corporate Roundup for Thursday The Wall Street Journal
03:51AM  Merck KGaA (MKGAF) Q2 Earnings Down Y/Y, Sales Flat Zacks
02:16AM  [$$] Merck KGaA Sales Edged Up, Confirms Outlook The Wall Street Journal
01:24AM  Merck KGaA profit dragged lower by liquid crystal decline, forex CNBC
01:20AM  Merck KGaA profit dragged lower by liquid crystal decline, forex Reuters
Aug-08-18 10:02AM  Health workers in Congo being vaccinated against Ebola - WHO Reuters
07:58AM  Mercks 60% price cut for hepatitis C drug nets company a big sales opportunity MarketWatch
Aug-07-18 04:30PM  Mercks Head of Human Resources Mirian M. Graddick-Weir to Retire; Steven C. Mizell Will Assume Role on Oct. 1 Business Wire
Aug-06-18 05:27PM  Patients who accepted infected kidneys cured of hepatitis C Associated Press
03:00PM  3 Healthcare Stocks to Buy for the Sector Rebound InvestorPlace
09:30AM  What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings? Zacks
09:03AM  Zacks Investment Ideas feature highlights: Merck and Amgen Zacks
07:40AM  Research Report Identifies Modine Manufacturing, Oxford Industries, Bottomline Technologies, NETGEAR, Potlatch, and Merck & Co. with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-03-18 05:52PM  Alexandrias Joel Marcus on Medicare-for-all, innovation and his companys Peninsula plans American City Business Journals
12:07PM  Aduro (ADRO) Q2 Loss Narrower Than Expected, Revenues Miss Zacks
11:26AM  Two Pharma Giants Successfully Navigate a Challenging Climate Zacks
11:23AM  Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval Zacks
09:30AM  PFE vs. MRK: Which Stock Should Value Investors Buy Now? Zacks
08:31AM  Congo to use Ebola vaccine as early as next week - health minister Reuters
06:30AM  Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1 Business Wire
Aug-02-18 10:19AM  Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q2 Zacks
Aug-01-18 04:12PM  Why The 'Heat Wave' For U.S. Pharma Could Continue This Month Investor's Business Daily
03:08PM  NYSE trader: American wealth and stock earnings are at record highs, so I can only be bullish Yahoo Finance Video
02:18PM  Healthcare Bulls Are Feeling Great After Earnings TheStreet.com
Jul-31-18 04:20PM  Pfizer Breaks Out As CEO Mulls Future Of Drug Price Rebates Investor's Business Daily
12:05PM  Why Sanofi Stock Should Run Higher Despite Mixed Earnings InvestorPlace
09:01AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:30AM  Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA® (lenvatinib) in Combination with KEYTRUDA® (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma Business Wire
Jul-30-18 06:45AM  European Medicines Agency Adopts Positive Opinion for KEYTRUDA® (pembrolizumab) Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer Business Wire
Jul-27-18 11:23PM  Edited Transcript of MRK earnings conference call or presentation 27-Jul-18 12:00pm GMT Thomson Reuters StreetEvents
01:49PM  Merck profit beats, but Keytruda sales fail to impress Reuters
12:25PM  Merck profit beats, but Keytruda sales fail to impress Reuters
12:16PM  Merck profit beats, but Keytruda sales fail to impress Reuters
11:15AM  Merck (MRK) Q2 Earnings & Sales Top on Keytruda Strength Zacks
10:35AM  Merck beats views on sales jumps for cancer drugs, vaccines Associated Press
10:30AM  How AbbVie Makes its Money Investopedia
10:20AM  Merck Beats Estimates and Raises Guidance, But Stock Plops 2% TheStreet.com
09:24AM  Stocks to Watch: Amazon, Intel, Twitter, Starbucks, Chipotle, Expedia, Exxon Mobil, Chesapeake, Merck The Wall Street Journal
08:55AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:54AM  Top 5 Things to Know in the Market on Friday Investing.com
08:37AM  Merck touts a 60% price cut, but the drug is outdated and on the way out MarketWatch
08:16AM  Merck (MRK) Tops on Q2 Earnings & Sales, Stock Up Zacks
08:07AM  [$$] Merck Cancer Drug Drives Second-Quarter Sales The Wall Street Journal
08:00AM  Merck (MRK) Surpasses Q2 Earnings and Revenue Estimates Zacks
06:59AM  Mercks Blockbuster Cancer Treatment Powers Profit Bloomberg
06:45AM  Merck Announces Second-Quarter 2018 Financial Results Business Wire
06:00AM  Merck & Co., Inc. to Host Earnings Call ACCESSWIRE
02:45AM  Pharma Favorites: 7 Healthy Picks in the Drug Sector Investopedia
Jul-26-18 07:41PM  [$$] Sutro Biopharma Banks $85.4 Million Series E for Cancer Drug Development The Wall Street Journal
04:57PM  5 Must-See Earnings Charts to End the Week Zacks
02:57PM  Merck Q2 Earnings Preview Benzinga
12:43PM  Bristol-Myers cancer ruling hits shares after strong earnings Reuters
10:15AM  3 Biotech Stocks Making Moves on News This Month ACCESSWIRE
07:55AM  ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions Zacks
07:30AM  Initiating Free Research Reports on Pfizer and Three Other Drug Makers Equities ACCESSWIRE
06:59AM  Bristol-Myers Q2 earnings rise, full-year forecast up on strong sales Reuters
06:45AM  KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma Business Wire
Jul-25-18 12:13PM  Merck's Keytruda Improves Survival in Head/Neck Cancer Study Zacks
08:41AM  Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile Benzinga
06:45AM  REPEAT/KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS 20) Business Wire
12:00AM  KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS 20) Business Wire
Jul-24-18 08:06PM  [$$] Congo Declares End to Ninth Ebola Outbreak The Wall Street Journal
04:12PM  [$$] Sutro Biopharma Strikes $1.6 Billion Drug-Development Deal With Merck The Wall Street Journal
12:15PM  Merck Announces Fourth-Quarter 2018 Dividend Business Wire
11:24AM  Merck (MRK) Q2 Earnings Coming Up: What's in the Cards? Zacks
06:45AM  Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine Business Wire
Jul-23-18 09:52PM  [$$] Chinas Latest Consumer Scandal: Unsafe Vaccines The Wall Street Journal
04:38AM  [$$] China's Latest Consumer Scandal: Unsafe Vaccines The Wall Street Journal
Jul-20-18 03:08PM  Merck reduced prices of small and insignificant drugs: An... CNBC Videos
01:59PM  Swiss, German drugmakers join U.S. price freeze Reuters
11:49AM  Merck Announces Plans To Cut Drug Prices Benzinga
11:23AM  Roche Hiked Cancer-Drug Prices Before Pledge to Keep Them Flat Bloomberg
11:16AM  MARKETS: Honeywell stock pops after raising full year guidance Yahoo Finance Video
11:11AM  Swiss, German drugmakers join U.S. price freeze Reuters
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. Merck & Co., Inc. has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., and Foundation Medicine, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Option Exercise34.8629,2081,018,17680,675Aug 06 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Sale65.2029,2081,904,36251,467Aug 06 04:49 PM
Karachun Rita ASr. VP Fince-Global ControllerAug 02Sale65.015,000325,04016,175Aug 02 05:07 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Option Exercise33.49228,0917,638,768938,788Aug 01 05:12 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Sale65.00228,09114,826,691710,697Aug 01 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Option Exercise36.56100,0003,656,000100,000Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.0034,0942,079,78562,766Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.00100,0006,100,1600Jun 19 10:55 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 15Sale59.669,972594,96345,717May 16 12:33 PM
Watson AshleySVP Chief Ethics & Com OfficerMay 01Option Exercise0.0010,441012,783May 02 12:19 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 01Option Exercise0.004,009052,609May 02 12:18 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise0.003,007022,205May 02 12:18 PM
GRADDICK WEIR MIRIAN MExe V-P, HRApr 16Sale58.0024,0001,392,00080,433Apr 17 05:56 PM
WEEKS WENDELL PDirectorFeb 09Option Exercise38.045,000190,2005,100Feb 09 04:48 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthFeb 09Option Exercise0.008,572045,780Feb 09 04:48 PM
WEEKS WENDELL PDirectorFeb 09Sale53.575,000267,833100Feb 09 04:48 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Option Exercise36.5650,9941,864,34150,994Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Option Exercise44.3052,0002,303,600153,484Jan 16 05:12 PM
Holston Michael JEVP, General CounselJan 16Sale61.6312,500770,37549,092Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,6083,118,97162,766Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,9943,142,7600Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Sale61.6360,0003,697,80093,484Jan 16 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 12Sale58.005,000290,000101,484Jan 16 05:12 PM
GLOCER THOMAS HDirectorNov 08Option Exercise38.045,000190,20010,100Nov 09 03:52 PM
GLOCER THOMAS HDirectorNov 08Sale56.205,000280,9835,100Nov 09 03:52 PM